Overview of the Champions TumorGraft® Process and Options
The Champions TumorGraft process begins with a piece of live tumor. It is best to plan for a personalized patient-derived xenograft (PDX) in advance of surgery/biopsy.
A piece of the patient’s living tumor is removed during surgery or biopsy and is implanted in mice. By implanting the tumor together with its microenvironment, Champions TumorGraft® PDX tumor molds continue to very closely resemble the patient’s tumor, with 94 percent genetic correlation to the tumor in the patient. Approximately 65 percent of most tumor types implanted will grow successfully in mice.
While the tumors are growing in the mice, the patient continues to receive regular cancer treatment therapy from their oncologist. This growth period generally takes two months or longer.
Our scientists work closely with treating physicians to determine which cancer drugs to test on the patient’s PDX tumor model. Our labs will administer these cancer treatments to the mice and measure the living tumor’s response to each drug regimen. Physicians receive a robust report on the effectiveness of each tested cancer therapy on the tumor model. With this information in hand, physicians can personalize each patient’s cancer treatment therapy.
Every Champions TumorGraft PDX model is preserved as a living sample for future patient use. These banked models can be regrown and tested in the event of cancer progression or recurrence.
The entire process (implantation through testing) typically takes 4-6 months.
Keep your patient’s tumor — and their options — alive by sending their tumor to Champions.